Obesity results from a chronic imbalance between energy intake and energy expenditure. Environmental factors, such as the increased availability of high caloric food or the decreased need for physical activity, contribute to its development and their influence is amplified by genetic predisposition. In recent years remarkable progress has been made in the understanding of the pathophysiology of obesity. Although most of the insights into the regulation of energy balance have been obtained in rodent models, the rare clinical cases of monogenic obesity provided evidence for the importance of several of these mechanisms in humans. The identification of leptin as a factor originating from adipose tissue and informing the brain about the status of energy reserves firmly established the concept of long-term regulation of body fat stores. The disappointing therapeutic results with leptin in obese patients could be explained by the fact that during evolution this hormone developed rather as a starvation signal than as an adiposity signal. It is conceivable that the pharmacological interference with mechanisms downstream of leptin, for example with the melanocortin pathway, might be therapeutically more promising. The discovery of new molecular mechanisms involved in the regulation of the differentiation and proliferation of adipocytes and the elucidation of their paracrine and endocrine functions have changed the traditional view of adipose tissue as an inert depot for triglycerides. The identification of new uncoupling proteins could modify the current concepts of the regulation of thermogenesis in humans. The remarkable progress in the identification of novel targets involved in the regualtion of energy balance should have a positive impact on the search for new antiobesity agents.
Background
Obesity as a medical problem Obesity is a serious health problem in industrialized countries. Its prevalence has been steadily increasing during recent years and this trend is particularly pronounced in children and adolescents. 1, 2 Changes in eating habits with readily available high-energy food on the one hand and a sedentary lifestyle with decreased physical activity on the other hand have been responsible for this phenomenon. 3 Since obesity is frequently associated with other diseases, such as diabetes and hypertension, 4 -7 it is essential to reduce body weight to prevent or treat these complications. However, diet and physical exercise are usually not very effective and even after successful weight loss most patients regain weight. 8 This is mainly, if not exclusively, the consequence of the activation of counterregulatory mechanisms, which tend to restore body weight to the previous set point even if this was pathological. 9 An improved understanding of the pathways regulating energy balance is therefore a prerequisite for a rational use of the existing treatments of obesity and for the design of effective and well-tolerated new anti-obesity drugs. 10 -12 In recent years the molecular mechanisms involved in the regulation of energy balance have been extensively studied. Several reviews discuss the latest developments in this field 13 -16 and their therapeutic implications. 17, 18 Despite the remarkable progress in the identification of new mechanisms, our understanding of the precise organization and hierarchy of the regulatory networks is far from complete. The present review is focused on the main pathways in the regulation of energy intake, storage and expenditure and related endocrine functions ( Figure 1 ). The complex interactions of neural and hormonal factors involved in the pathophysiology of obesity will be illustrated by selected examples and the suitability of these systems as possible targets for new anti-obesity drugs will be discussed.
Genetic vs environmental factors
The degree to which genetic factors contribute to the pathophysiology of obesity is currently estimated to range between 25 and 40%. 19 In most cases, susceptibility to obesity is a polygenic trait. 20, 21 As long as access to food is limited and energy expenditure is high, the body weight of susceptible individuals barely differs from that of normal subjects ( Figure 2 ). However, under conditions of high fat intake or reduced energy expenditure, body weight in a genetically susceptible subpopulation will increase more than in the rest of the population 20, 21 ( Figure 2 ). Such a heterogeneous response to environmental factors can also be observed in rodents, for instance during a high-fat diet. 22 However, it is unknown whether the same genetic factors are responsible for the weight gain after high fat consumption in these different species. Several single gene mutations have been described in patients with severe obesity. While these rare cases cannot explain the epidemic increase in the prevalence of obesity, they make it possible to relate clinical to experimental findings. 21 Similar molecular defects have been observed in genetically obese rodents or can be produced by genetic modifications such as gene knock-out or overexpression in mice. 23 These models have helped enormously in elucidating the molecular regulation of energy balance. 24, 25 Energy balance and evolution The endogenous systems regulating energy balance have developed during the course of evolution, when the conservation of energy reserves and the efficient replenishment of exhausted energy stores were essential for survival and reproduction. 26, 27 Since evolution is a slow process and cannot foresee future developments, 28 several of the mechanisms that were useful in the pre-industrialized world may no longer be optimal, but have not yet adapted to the present environment. These systems will respond to therapeutic interventions such as dieting as if the organism were challenged by starvation, and thereby reduce the therapeutic efficacy of low energy intake. After a period of dieting they will favour the rapid build-up of the lost energy reserves and thereby cause relapse and rebound. 9, 29 The mechanisms that helped our ancestors to cope with 'feast and famine' situations 26 have today turned into obstacles to an efficient treatment of obesity. Furthermore, the therapeutic goals of modern medicine, namely to extend longevity and to prevent complications at a late age, are not in accordance with the goals of evolution, which aims at physical fitness and fertility at a young age. 29 
Regulation of food intake

Leptin pathway
The discovery of leptin 30 has profoundly changed our concepts of the long-term regulation of energy balance. For the first time a factor from white adipose tissue was identified that informed the brain about the energy reserves of the body. Soon after the first publication on leptin, its receptors were identified. 31 Their defective function is the pathophysiological basis for obesity in db=db mice and fa=fa rats, whereas the lack of circulating leptin causes obesity in ob=ob mice. 32 It took only a little while before the corresponding defects were described in patients with severe forms of hyperphagia and obesity. 33, 34 This demonstrated clearly that leptin is as important in humans as in rodents and plays a central role in the regulation of appetite.
Several recent reviews describe the actions of leptin in physiology and pathophysiology in much detail. 35 -37 Briefly, Figure 1 The size of body fat mass is the result of the balance between energy intake and energy expenditure. If intake is too high for a given expenditure or if expenditure is too low for a given intake, obesity will develop over the long term. An imbalance between energy intake and expenditure can be caused by genetic or environmental factors. In most cases, both genetic and environmental factors act together in the pathogenesis of overweight and obesity. Adipose tissue is not only an important energy depot, but also an active endocrine organ, which has an influence on cardiovascular and metabolic function, fertility and endocrine systems. It is therefore understandable that obesity is associated with various cardiovascular, metabolic and endocrine diseases. Figure 2 Under conditions of normal energy intake and expenditure, subpopulations with a normal genetic background or with a genetic susceptibility to obesity have comparable body mass indices (BMI, expressed as mass in kg divided by squared height in m). When energy intake is high, the BMI distribution curve shifts to the right. This shift is more pronounced in a subpopulation with genetic susceptibility for obesity. An additional reduction in energy expenditure results in a further rise in BMI and a wider separation of the subpopulations. Patients with rare monogenic forms of obesity show a marked increase in BMI irrespectively of the environmental conditions. Molecular pathways to obesity KG Hofbauer leptin is a cytokine-like molecule with a molecular mass of 16 kDa synthesized mainly, but not exclusively, in white adipose tissue. Its synthesis occurs in proportion to adipose cell size and number, but also in response to acute stimuli. It is released into the blood and reaches its receptors in the brain via facilitated passage across the blood -brain barrier.
In the arcuate nucleus of the hypothalamus leptin binds to cytokine type I receptors, which signal through the JAK (janus kinase) -STAT (signal transducer and activator of transcription) pathway. Activation of these receptors results in a reduction of food intake, which is mediated through various downstream mechanisms including neuropeptide Y (NPY) and a-melanocyte stimulating hormone (a-MSH). 35 -37 Although leptin fulfilled all criteria for an adiposity signal, 14 it soon became apparent that it is not only an appetite suppressant. Numerous other actions of leptin have been described, such as effects on the endocrine system and on reproduction. 38, 39 These actions link the regulation of energy balance to fertility and have probably been of importance in the context of evolution. It is possible that the main message leptin conveyed to the brain was that energy stores were sufficiently large to ensure reproductive success. Conversely, falling plasma leptin levels during periods of decreasing body fat stores would have signalled to the brain to conserve energy and withhold reproductive function. 40 Other actions of leptin could also relate regulatory functions to energy reserves. The impaired immune response during starvation might at least in part be the result of low leptin plasma concentrations. 41 It is unclear how the effects of leptin on angiogenesis 42, 43 or on steatosis of muscle and liver 44, 45 fit into whole body regulation. Taken together, these diverse effects support the notion that leptin acts as a starvation hormone to adjust important physiological processes to body fat mass rather than as a satiety hormone to prevent extensive accumulation of body fat mass. 36 Such considerations help to explain the disappointing results reported in the first trial of leptin in obese patients. 46 In these studies leptin was administered daily for 24 weeks at different doses in humans. Only the highest dose, which increased plasma leptin approximately 20-fold above basal levels, resulted in a decrease of mean body weight, but even after this dose the response was highly variable. This is in contrast to the positive effects of leptin replacement treatment in a patient with leptin deficiency. In this case, the restoration of plasma leptin to normal values was sufficient to induce a progressive reduction in body weight over a 1 y treatment period. 47 Recently it was reported that patients with partial leptin deficiency had an increased body fat mass. 48 This suggests that a relatively small drop in plasma leptin below normal values is sensed by the systems that control energy balance. Hence it is likely that, in this subgroup of patients, treatment with leptin would also be effective. 48 These observations indicate that increases in plasma leptin are much more effective in the low than in the high concentration range (Figure 3 ). This is also consistent with the notion that the body is better protected against weight loss than against weight gain. 26 Conversely, the limited efficacy of leptin in obese patients could be due to the development of leptin resistance after prolonged exposure to increased plasma leptin concentrations. 13 Such a phenomenon would also explain why the high plasma leptin levels in obese subjects 49 obviously do not induce an appropriate reduction in appetite. Leptin resistance could be caused by various mechanisms such as a restricted access of leptin to its hypothalamic sites of action or an impaired intracellular signal transduction. It has indeed been shown that leptin enters the brain by a saturable mechanism. 50 It has also been demonstrated that prolonged stimulation of the JAK -STAT pathway activates inhibitory components such as suppressor of cytokine signalling 3 (SOCS-3), which limit the response to agonists. 51 Chronic administration of a high-fat diet to rats resulted in both a reduced uptake of leptin into the brain and a decreased response of the STAT pathway in central neurones. 52 While the explanation for the limited efficacy of high plasma levels of leptin in the pathophysiology or therapy is still open, additional information was obtained from experimental and clinical studies with axokine, a derivative of ciliary neurotrophic factor (CNTF). 53 The appetite suppressing and weight-reducing effect of axokine was incidentally detected when this cytokine was investigated as a possible treatment for amyotrophic lateral sclerosis. Moreover, it was reported that after termination of treatment with Figure 3 Plasma leptin concentrations are positively correlated with body fat mass (thick dashed line) and negatively correlated with food intake (thick solid line). The set point of these parameters under normal conditions is indicated by the thin dashed lines. The leptin=food intake relationship can be viewed as a concentration -response curve. The left part represents the situation during starvation, when plasma leptin falls to low values, or during replacement therapy with exogenous leptin in leptin-deficient patients, whereby plasma leptin is raised towards normal levels. In this concentration range, positive or negative changes in plasma leptin have a profound effect on food intake (steep slope of the curve). The right part of the curve represents the situation in obese patients with elevated plasma leptin. Even at very high values leptin has only a rather modest effect on food intake. It is obvious that, in these patients, any further rise in plasma concentrations such as during pharmacotherapy with exogenous leptin will only have small effects (shallow slope of the curve). The two sections of the leptin concentration -response curve can also be interpreted as corresponding to the different role of leptin during evolution and the post-industrial period. During the course of evolution, leptin probably acted mainly as a starvation signal (steep slope, maximum gain), whereas in the postindustrial period it acts rather as an adiposity signal (shallow slope, minimum gain). Adapted from ref. 29. axokine in rodents no rebound weight gain, which is usually seen after treatment with conventional anti-obesity drugs, was observed. 53 These results are particularly interesting because axokine binds to a different receptor but probably acts through the same intracellular signalling pathway as leptin. Apparently the therapeutic effects of axokine were neither affected by limited access to its hypothalamic sites of action nor by inhibition of intracellular signalling. It would be interesting to find out why a modified cytokine, which has no apparent physiologic function in the regulation of appetite, shows a more promising therapeutic response than the endogenous ligand leptin, which is known to play a central role in the physiology and pathophysiology of energy balance. 54 Mechanisms downstream of leptin Activation of leptin receptors in the arcuate nucleus initiates a cascade of downstream events. These include the inhibition of neurones containing NPY, an orexigenic peptide, and the stimulation of neurones containing pro-opiomelanocortin (POMC), the precursor of a-MSH, an anorexigenic peptide 13, 14 ( Figure 4 ).
NPY is a potent and effective orexigenic agent upon acute and chronic administration. 55, 56 Continuous intracerebroventricular infusion of NPY for 7 days in rats produced an obesity syndrome with typical endocrine and metabolic abnormalities. 57 Early results with antisense oligonucleotides against NPY or NPY receptors suggested an important role of endogenous NPY on basal and starvation-induced food intake. 58 However, the receptor subtype which mediates the orexigenic effects of NPY is still not known.
For a long time the Y1 receptor or a so-called atypical, Y1-related receptor was implicated in the control of feeding. 55 When a new NPY receptor, the Y5 subtype, was described, it appeared to fulfil the pharmacological criteria for being the food-intake receptor. 59, 60 Experiments with antisense oligonucleotides 61 -63 and an antagonist of this receptor subtype 64 looked promising. However, other authors reported no effects with their Y5-receptor blockers, 65 or suggested that the compound used in earlier studies 64 may have nonspecific effects. 66 Recent reports appear to again provide evidence for an important role of Y1 receptors in the regulation of feeding. 67 It is therefore still unclear which receptor subtype is the most promising target for therapeutically active NPY antagonists. 68 NPY gene knock-out in lean mice did not produce an abnormal phenotype. 69 Whereas NPY gene knock-out in ob=ob mice resulted in a reduction in body weight, all combinations of other obesity models with NPY gene knockout had no effect. 70 Moreover, knocking out the genes encoding for NPY receptor subtypes Y1 or Y5 did not result in hypophagia but rather in late-onset mild obesity. 71, 72 Taken together, the previous notion that endogenous NPY plays a dominant role in the regulation of food intake is not supported by experimental data. It cannot be excluded that the lack of a phenotype after the loss of NPY is due to redundant control systems or efficient compensatory mechanisms. However, such an explanation is unlikely because the genetic ablation of other hormones or precursors such as a-MSH or POMC does result in persistent functional defects. 23 a-MSH is a posttranslational processing product of POMC and acts at various melanocortin receptor (MC-R) subtypes. 73, 74 In the hair follicles of the skin, a-MSH acts on the MC1-R subtype to increase melanin production, which results in a dark fur colour. An endogenous inhibitor, the so-called agouti protein, blocks the binding of a-MSH to the MC1-R and thereby modulates the effects of the hormone. 75 In the hypothalamus, a-MSH acts on MC3-R and MC4-R subtypes resulting in decreased appetite and, in the long-term, in reduced body weight. At this site another endogenous inhibitor, named agouti-related protein (AGRP), modulates the effects of a-MSH by inhibiting its binding to the receptors. 73, 74 In genetically obese agouti y mice a single gene defect leads to the concomitant overexpression of agouti protein in the skin and in the hypothalamus. The resulting persistent inhibition of a-MSH at both sites explains the combined phenotype of yellow fur colour and increased body fat mass. 76 
Figure 4
The ob-gene is mainly but not exclusively expressed in white adipose tissue. The ob-gene product, leptin, is released into the blood and acts at receptors in peripheral organs and the brain. The activation of receptors in the arcuate nucleus of the hypothalamus leads to a reduced activity of neuropeptide Y (NPY), a strong orexigenic agent, and an increased activity of a-melanocyte stimulating hormone (a-MSH), a strong anorexigenic agent. The endogenous inhibitor of a-MSH, agouti-related protein (AGRP), is suppressed by leptin, which also leads to an increased a-MSH signalling. The reduced signalling through the NPY receptor subtypes Y1 and Y5 and the increased signalling through the melanocortin (MC) receptor subtypes 3 and 4 result in a decrease in food intake and an increase in energy expenditure. As a consequence of the reduced food intake and increased energy expenditure the adipose tissue depots become smaller and the production of leptin decreases, which closes the feedback loop. However, leptin also acts through mediators other than NPY and a-MSH, and, conversely, NPY and a-MSH are also influenced by factors other than leptin (dashed lines). Both the NPY-and the MC-systems also influence endocrine and reproductive function by direct interference with hormonal systems. Furthermore, a sufficient amount of adipose tissue is a prerequisite for sexual maturation and fertility (broken line).
In contrast to the negative results with NPY-or NPYreceptor knock-out mice, genetically modified mouse strains provided consistent evidence for an important role of a-MSH in the regulation of energy balance. Elimination of the agonist a-MSH in POMC knock-out mice 77 or of its receptors in MC3-R or MC4-R knock-out mice 78 -80 produced an obese phenotype. Overexpression of the endogenous inhibitors agouti protein or AGRP 75, 81 also resulted in obesity. The findings obtained in genetically modified rodent models have been confirmed by pharmacological studies with agonists and antagonists of MC-Rs. 82 -84 Moreover, corresponding genetic forms of obesity were found in humans. A POMC mutation, which resulted in severe, early childhood obesity with adrenal insufficiency and red hair pigmentation, 85 and various different mutations of the MC4-R linked with obesity 86 have been described in humans. It is estimated that MC4-R mutations are a causal pathogenetic factor in approximately 3 -4% of patients with severe obesity. 86 The strong evidence for an important role of a-MSH contrasts sharply with the weak evidence for a comparable role of NPY. It may be that a-MSH controls food intake under basal conditions, whereas NPY is only important during severe starvation. This would imply that a-MSH exerts a tonic suppression of appetite whereas NPY is only needed for transient stimulation of appetite. In this context it is interesting to note that the duration of action of centrally administered AGRP is exceptionally long. 87 Whether this finding mirrors a similar long-lasting effect of endogenous AGRP is not known, but if so it would add to the strength of this regulatory pathway. Such considerations have significant implications for drug discovery. From the currently available information it would appear that agonists of the MC4-R or inhibitors of AGRP would be more promising appetite suppressants than antagonists of NPY at any of its receptor subtypes.
Other pathways
In recent years many new peptides that play a role in appetite regulation have been identified. 13, 17, 18 Some of them appear to have additional effects and it is not clear which of their diverse actions prevail under physiological or pathological conditions. Orexins for instance stimulate food intake but also act on the orexin-2 receptor subtype (OX2-R) to influence arousal. 88 Orexin knock-out mice show narcolepsy 89 and a spontaneous mutation of OX2-R with similar symptoms is known in dogs. 90 Melanin-concentrating hormone (MCH) is another orexigenic peptide produced in the lateral hypothalamus. 91 Its overexpression leads to obesity whereas its genetic ablation leads to hypophagia and leanness. 92, 93 Both orexins and MCH are considered as possible effector systems of NPY or POMC neurones. 14 It is obvious that not all orexigenic or anorexigenic mediators are controlled by leptin. Vice versa, the neuropeptides in the downstream leptin pathway are also influenced by other systems. NPY for instance is modulated by insulin, glucocorticoids and by ghrelin, a growth hormone secretagogue with orexigenic activity. 56, 94 Whether this regulation is separate from or related to the leptin pathway is presently not known (Figure 4) .
Regulation of energy expenditure and storage
Energy expenditure Many of the centrally active mediators involved in the control of food intake also affect energy expenditure in rodents. Chronic administration of leptin has been shown to increase energy expenditure in mice and comparable observations were made with a-MSH. Conversely, orexigenic principles such as NPY appear to reduce energy expenditure. 95, 96 However, in humans no such effect of leptin could be observed. 46, 47 This could indicate a basic difference in the regulatory systems controlling energy expenditure. In rodents, changes in sympathetic tone lead to activation and, in the long-term, overexpression of uncoupling protein 1 (UCP 1) in brown adipose tissue, whereas in humans this system is only active during fetal life 97, 98 ( Figure 5 ). However, chronic stimulation of b3-adrenoceptors, which activate UCP 1 via increased cAMP levels, could lead to an interconversion of white into brown adipose tissue and thereby generate the substrate for a thermogenic effect of b-adrenergic stimulation in humans. 99 The recent discovery of other UCPs 100 raised much interest, but to date their precise functional role in humans is still unclear. UCP 2 is widely distributed in the body. It seems to regulate the secretion of insulin from pancreatic b cells by lowering the intracellular levels of ATP through its uncou- Figure 5 The brain controls the function of brown adipose tissue (BAT) via the sympathetic nervous system. The activation of b3-adrenoceptors induces a rise in intracellular cAMP, which acutely leads to an increased activity and chronically to an increased expression of uncoupling protein 1 (UCP 1). The resulting thermogenesis raises body temperature and the increased energy expenditure may in the long term lead to a loss of body fat. These changes are probably sensed by the brain and sympathetic tone is re-adjusted according to the present needs. It is possible that, in species without brown adipose tissue, long-term stimulation of b3-adrenoceptors in white adipocytes induces their conversion to brown adipocytes thereby generating the substrate for b3-adrenoceptor mediated thermogenesis.
Molecular pathways to obesity
KG Hofbauer pling action. This in turn increases the membrane potential via an effect on ATP-sensitive potassium channels and thereby results in an inhibition of insulin secretion. 101, 102 UCP 3 is mainly located in skeletal muscle, which is the largest heat-producing tissue in the human body. However, the expression of UCP3 increases during starvation, when heat production should be diminished rather than increased. 103 This finding is difficult to reconcile with a role of UCP3 in the overall regulation of energy expenditure.
Gene ablation studies in mice have not provided experimental evidence for a role of UCPs in the pathogenesis of obesity. Gene knock-out of UCP 1 resulted in an increased sensitivity to cold, but not in an enhanced susceptibility to weight gain. 104 This suggests that UCP 1 is more important for thermoregulation than for the control of body fat via energy expenditure ( Figure 5 ). Mice with UCP 2 or UCP 3 deficiency neither showed hypothermia nor decreased energy expenditure. 101, 105, 106 Since their body weight was also not affected, it appears that these UCPs are not necessary for the control of energy balance.
Energy storage
While in the past adipose tissue was considered as an inert energy depot, it is now clear that adipocytes have a variety of functions, which are closely controlled by neural and hormonal mechanisms. 107, 108 Adipocytes produce and release hormones and mediators in an autocrine, paracrine and endocrine manner ( Figure 6 ). By secreting angiotensinogen, the precursor of the vasoconstrictor hormone angiotensin II, adipocytes could influence blood pressure and renal function. 109, 110 By releasing free fatty acids and tumour necrosis factor a (TNF a) they influence insulin sensitivity in muscle and liver. 108 Another recently described factor, resistin, was claimed to be the missing link between obesity and insulin resistance. 111 It might also mediate the beneficial effects of thiazolidinediones, which improve insulin sensitivity in skeletal muscle by acting on peroxisome proliferator activated receptor g (PPARg) in adipocytes. 111 However, conflicting data were recently reported and the original results remain to be confirmed. 112, 113 The mechanisms controlling pre-adipocyte maturation, proliferation and differentiation into white and brown fat cells have been extensively studied 114 -117 (Figure 7 ). Genetically modified mouse strains provided striking examples of the importance of specific regulators. Knock-out of the high motility group I-C (HMGI-C) gene in mice results in a phenotype that almost totally lacks adipose tissue. 118 These mice are protected from weight increase during a high-fat diet. When the gene knock-out is performed in ob=ob mice, obesity does not occur. 118 From a therapeutic point of view this intervention looks attractive but is most probably not a viable approach. Particularly in the light of the various metabolic and endocrine functions of adipose tissue, its complete elimination may create more complications than it would prevent. 119 However, the modulation of fat cell phenotype 120 or the conversion of white into brown fat cells 121, 122 may be valid therapeutic options.
Integrative pathways and networks
The remarkable progress in the elucidation of new mechanisms involved in the regulation of energy balance raises some principal questions. Why is a function such as food intake controlled by so many central and peripheral systems? The common explanation that important functions of the body Figure 6 White adipose tissue (WAT) is not an inert depot for the storage of triglycerides but has various auto-, para-and endocrine functions, which are under hormonal and neural control and can be influenced by drugs such as the thiazolidinediones. The following examples for endocrine functions of WAT are given: secretion of leptin, which affects appetite by a central action; release of tumour necrosis factor a (TNFa), resistin or free fatty acids (FFA), which all influence insulin sensitivity in liver and skeletal muscle; and production of angiotensinogen, the precursor of the vasoconstrictor peptide angiotensin II, which reduces renal sodium excretion by direct and indirect effects on the kidney. Figure 7 After commitment of mesenchymal stem cells to adipogenesis, proliferation of pre-adipocytes ensues, which is regulated by factors such as high mobility group I-C (HMGI-C). The differentiation of preadipocytes to mature adipocytes is controlled by peroxisome proliferation activator receptor g (PPARg) and PPARg-co-activator 1 (PGC-1). The latter is also important for the interconversion between white and brown adipocytes. Recently, a translational activator binding protein (4E-BP1) was identified as another factor that determines the phenotype of adipocytes.
require redundant control systems is probably too superficial. There are several examples of single gene mutations in animals or man which clearly show that the loss of a key mechanism in a pathway of appetite regulation cannot be compensated for. 21, 23 There is similar evidence from other physiological systems that regulate equally important functions. Renal water excretion, for instance, which is essential for the maintenance of body osmolality, is regulated by antidiuretic hormone. There is no back-up system for this hormone and its deficiency or a mutation of its renal receptors results in persistent diabetes insipidus. 123 -125 What is the interrelationship between the various mechanisms in the regulation of energy balance and what is their hierarchy as far as efficacy and time course are concerned? Could mechanisms that appear to control food intake have their more important effects in other regulatory loops? It is for instance conceivable that leptin does not primarily control the size of adipose tissue but rather regulates reproduction 126 and other endocrine functions. 127 Several recent publications report a link between the regulation of energy balance and glucose metabolism. Central administration of a-MSH has a significant effect on peripheral glucose uptake. 128 Insulin receptors and insulin signalling proteins in the brain appear to influence energy disposal in the periphery and reproductive function. 129, 130 Striking similarities between these effects of insulin signalling on fertility, metabolism and longevity in rodents, Drosophila or Caenorhabditis elegans have been demonstrated. 131 -133 Does body fat mass only play a permissive role for the maintenance of other, more important functions of the organism? This would explain why fat reserves are apparently not as tightly controlled as other biological parameters and would question the need for an accurate set point. Furthermore, energy reserves are more critical in small rodents than in humans, who could therefore afford a looser control of body fat mass. 134 The enormous progress in the identification of mechanisms involved in energy homeostasis will also have an impact on the search for new anti-obesity drugs. 17, 18 There the main challenge has shifted from target identification to target validation and proof of concept in relevant animal models and in clinical trials. In view of the complexity of the regulation of energy balance it is difficult to find anti-obesity agents that selectively reduce appetite or increase energy expenditure while not affecting other parameters. However, the high medical need for effective and safe drugs justifies the intensive efforts in drug discovery, which are aiming at the development of new anti-obesity agents with better efficacy and tolerability.
